The U.S. Food and Drug Administration has fast-tracked Amgen Inc.’s heart failure drug omecamtiv mecarbil.
Visual prosthetic company Second Sight Medical Products late Thursday announced a public offering of 7.5 million shares.
Total revenues and net income beat analyst expectations for Thousand Oaks biotech giant Amgen Inc. during the first quarter, the company announced Thursday.
Amgen Foundation on Tuesday announced a $2 million contribution to more than a dozen organizations in Los Angeles and Ventura counties to help vulnerable populations impacted by COVID-19.
Westlake Village-based Arcutis Biotherapeutics on Monday appointed Halley Gilbert to its board of directors. effective May 1.
At a time when many other biotech companies have curtailed clinical trials, Arcutis Therapeutics has enrolled its first patient in a Phase 1 study of hand eczema topical drug ARQ-252.
MannKind Corp. on Wednesday announced it received a $4.9 million loan from JPMorgan Chase Bank as part of the federal CARES Act Paycheck Protection Program.
Health care systems such as Kaiser Permanente have seen a “leveling off” of COVID-19 cases, with hospital admissions to the ICU more manageable compared to two weeks ago.
The Coalition of Kaiser Permanente Unions said it reached an agreement with the health care giant.
During the COVID-19 outbreak, Kaiser Permanente has temporarily closed select medical offices while others will limit services in an effort to control exposure to the virus.
Simulations Plus has acquired French medical software company Lixoft, further expanding its drug simulation capabilities and broadening its presence in Europe.
Amgen Inc. and Seattle-based Adaptive Biotechnologies on Thursday announced a strategic partnership to discover and develop a treatment for COVID-19.
Amgen Inc. has purchased 49 percent of shares for Amgen Astellas BioPharma, the result of a 2013 joint venture between Japanese company Astellas Pharma and the Thousand Oaks biotech giant. Financial terms of buyout were not disclosed.
Second Sight Medical Products Inc. on Monday announced it will lay off 84 of its 108 employees effective March 31 in response to COVID-19 challenges, the first step toward the end of the Sylmar company.